China grants conditional approval for Merck’s COVID treatment

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases
By Reuters on December 30, 2022

China has granted conditional approval for the import of Merck’s COVID-19 treatment Molnupiravir, China’s medical products regulator said today.

Molnupiravir, developed by Merck, is approved to be used in adult patients who have mild-to-medium COVID infection and a high risk of progressing to severe cases, according to China’s National Medical Products Administration.

Edits by EP News Bureau

 

COVID treatmentMerckNational Medical Products Administration
Related Posts

Akums Group enters into a partnership for European market expansion

Mankind Pharma and Innovent Biologics partner to license and commercialise Sintilimab

Corona Remedies pledges ₹25 cr towards CSR

Indian pharma companies focus on innovative research in foreign countries through dedicated entities

Namit Joshi takes charge as Chairman of Pharmexcil

Eco-conscious packaging: A strategic opportunity

Prothix LifeSciences partners with Oviya MedSafe
Comments (2)
Add Comment
  • soundos

    thanks for sharing such a nice information

  • djamila_st

    This article is an appealing wealth of informative data that is interesting and well-written. I commend your hard work on this and thank you for this information.